Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
190 participants
INTERVENTIONAL
2002-01-31
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
NCT03288129
A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
NCT01393743
A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children
NCT05274035
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
NCT01161524
Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
NCT00004817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Enzyme-inducing placebo TID
Placebo
Enzyme-inducing placebo TID
2
Enzyme-inducing Talampanel 35 mg TID
Talampanel
Enzyme-inducing Talampanel 35 mg TID
3
Enzyme-inducing TLP 50mg TID
Talampanel
Enzyme-inducing TLP 50mg TID
4
Non-enzyme-inducing placebo TID
Placebo
Non-enzyme-inducing placebo TID
5
Non-enzyme-inducing TLP 25mg TID
Talampanel
Non-enzyme-inducing TLP 25mg TID
6
Non-enzyme-inducing TLP 35mg TID
Talampanel
Non-enzyme-inducing TLP 35mg TID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Talampanel
Non-enzyme-inducing TLP 35mg TID
Placebo
Enzyme-inducing placebo TID
Talampanel
Enzyme-inducing Talampanel 35 mg TID
Talampanel
Enzyme-inducing TLP 50mg TID
Placebo
Non-enzyme-inducing placebo TID
Talampanel
Non-enzyme-inducing TLP 25mg TID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have diagnosis of partial seizures
* At least 3 observable partial seizures a month
* Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.
Exclusion:
* Patients on Valproic acid, and Felbamate
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Teva Branded Pharmaceutical Products R&D, Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IXL-201-14-189
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.